Abortion
Texas Heartbeat Act
Currently, there is only one big bioethical story –
the new Texas abortion law. It has provoked
newspaper articles and letters, TV programmes, court
hearings, debates, website hacking, marches, fights
and much more.
It is the culmination of 48 years of
campaigning. In 1973, the US Supreme Court
ruled, in the case of Roe v.
Wade, that a woman had the constitutional
right to an abortion before viability of her unborn,
namely at about 24 weeks. To call it a
contentious ruling would be a gross underestimate.
So, for almost five decades, the US pro-life
constituency has been pressing for repeal, or at
least some limitation, of this abortion
legislation. For instance, in July 2013, the
first Texas foetal heartbeat bill (HB 1500) was
introduce by Phil King, a member of the Texas House
of Representatives. However, the bill was
never passed. Now, in 2021, a more serious
challenge has finally emerged.
On 11 March 2021, the Texas Heartbeat Act (Senate
Bill 8, SB8) was introduced into the Lone Star State
legislature by Senator Bryan Hughes. After
debates and votes in both the Texas Senate and
House, it was signed into law by the Texas Governor,
Greg Abbott, on 19 May. And it came into
effect on 1 September.
This highly-restrictive Act has banned abortion
throughout Texas after six weeks of a pregnancy,
that is, after the detection of a foetal
heartbeat. It makes an exception for a medical
emergency, but not for cases of rape or incest.
Pro-abortion healthcare workers and women’s groups
have criticised it because of its earliness of 6
weeks, problems associated with cardiac activity
detection, its intrusion into women’s rights, its
disproportionate effect on black and low-income
women and those who live far from abortion
facilities, and so on. Yet the Act was
democratically passed by members of both the Texas
Senate and House, for instance, in the latter by 81
to 63.
Enraged, abortion providers, such as Planned
Parenthood, and rights groups, such as the American
Civil Liberties Union (ACLU), asked the Supreme
Court on 30 August to intervene and issue an
emergency block on the legislation. The
Supreme Court, with its 6-3 conservative majority,
cited procedural issues and turned down the request,
acknowledging that aspects of the Heartbeat Act
would continue to be challenged in the lower
courts. So on 1 September, the Act came into
effect. And because an estimated 85% of Texan
abortions are performed after six weeks, access to
almost all abortions in Texas has since been denied.
President Joe Biden has criticised the Act, calling
it ‘extreme’ and saying it ‘blatantly violates the
constitutional right established under Roe
v. Wade.’ The Biden administration
announced it plans to sue Texas on the basis that
the Act ‘illegally interferes with federal
interests’.
Accordingly on 9 September, the US Justice
Department went to court arguing that the Act was
unconstitutional. On 6 October, Judge Robert L
Pitman issued an order blocking the Act. He
called it ‘flagrantly unconstitutional’ and a
violation of Roe v. Wade.
The Judge said he would ‘not sanction one more day
of this offensive deprivation of such an important
right.’ However, on 8 October, the US Fifth
Circuit Court of Appeals put an administrative stay
on Pitman’s order. As a consequence, most
abortions in Texas remain illegal.
Meanwhile, the US Supreme Court declined to
intervene and hence the Texas law remained
temporarily in effect, but the Court unusually heard
legal arguments on 1 November. In a three-hour
meeting, the Justices were asked to decide whether
Texas abortion providers and the Department of
Justice – in effect the Biden administration – are
allowed to contest the state's new Act. One of
their arguments is that the law was drafted in such
a way as to evade legal review in federal
courts. It is thought that a decision from the
Supreme Court may come before the end of November
and that it will allow the lawsuit of the abortion
providers, but not that the Department of Justice,
to proceed. That would be before the
Mississippi court arguments begin on 1 December (see
below). In the meantime, abortions in Texas
have fallen by 50% since the law went into effect on
1 September.
A novel feature of the Act is that it allows ‘a
private right of civil action’ so any private
citizen can sue anyone who ‘aids and abets’ an
illegal abortion. Thus, an ordinary American,
from Texas or elsewhere, can seek a minimum of
$10,000 (£7,200) in damages in a civil lawsuit
against abortion providers and doctors and anyone
else, maybe clinic staff, family members or clergy,
who support the abortion. Opponents have
called this ‘a bounty-hunting scheme’.
On 20 July, with the prospect that the Supreme
Court’s consideration of Dobbs
v. Jackson Women’s Health Organization could
overturn the colossus of Roe v.
Wade, Governor Abbott signed the so-called
Abortion Trigger Bill. This proactive
‘trigger’ law would take effect after 30 days if Roe
v. Wade were overturned, or
if a court ruling or amendment allowed states
individually to prohibit abortions. The Bill
would prospectively ban all abortions in Texas,
without exemption, beginning from
fertilisation. Texas has therefore joined at
least 10 other US states which have already passed
similar measures. These would allow each state
to devise its own abortion laws and would in effect
protect all unborn children from abortion.
And what does the great American public make of all
this? Is Texas different from the other 49
states? When a Pew Research Center poll asked
about abortion, the overall US figure was that 59%
agreed it should be legal in all/most cases.
On the other hand, the equivalent figure from Texas
folk was only 45%. Moreover,
another poll conducted in April found that nearly
half of the state’s voters supported a six-week ban
on abortions. In other words, Texas is
fundamentally a pro-life state.
Dobbs v. Jackson Women’s
Health Organization
In the shadow of the novel and contentious Texas
Heartbeat Act and its six-week ban of abortion sits Dobbs
v. Jackson Women’s Health Organization.
The Supreme Court will hear this challenge to
Mississippi’s law that bans almost all abortions
after the 15th week of pregnancy. The hearing
is due to start on Wednesday 1 December.
Judgement is expected in the Summer 2022.
Lynn Fitch, the Mississippi Attorney General, has
said that she is looking forward to the opportunity
to convince the Court that there is no
constitutional right to abortion and that Roe
v. Wade should be
overturned. This is a big and bold case.
Abortion in America is in flux.
IVF and ARTs
Fertility rate plummets
Data recently published by the Office for National
Statistics (ONS) show the total fertility rate in
England and Wales fell to 1.58 children per woman
during 2020. This is the lowest figure since
records began in 1938.
This has been an unmistakeable trend. This
current rate is 4.2% lower than in 2019 and 3.1%
lower than the previous record low in 2001.
Why so? Among the reasons are, easier access
to improved contraception, delays in starting a
family because of career pressures and unstable
relationships, the trend towards fewer offspring,
financial uncertainty and the formidable cost of
raising children. And the Covid-19 pandemic
will have created its own negative physical and
emotional impacts and accelerated this trend.
According to the ONS there were 613,936 live
births in England and Wales during 2020.
Almost a third (29.3%) of these were among women
who were born outside the UK. The total
fertility rate among these foreign-born mothers
bucked the trend and increased slightly to 1.98.
The demographics and its warnings are
simple. The necessary replacement rate for
any country to maintain a steady population – that
is, neither growing nor declining – is reckoned to
be 2.1 children per woman. In 1960, the
world fertility rate was 4.9 children per woman
aged between 15 and 44, assumed to be her
child-bearing years. At the turn of this
century, it was down to 2.6, and by 2040, it is
predicted to be something like 1.8. The UK’s
latest rate of 1.58 is part of a trend
particularly obvious among Western and rich
countries in the developed world. It is a
combination of low fertility and high abortion
rates – currently in the UK almost a quarter of
pregnancies end in abortion.
Does it matter? Yes, it does. The
negative consequences of such plummeting fertility
rates and the consequent numerical reductions in
children will impact the health and welfare of
future ageing populations, including economic
growth, affordable pensions, adoptions, medical
resources and so on. The effects will be
profound. Some call it the ‘demographic
cliff’.
New plans for IVF storage
In early September, the UK government announced
its intention to extend the IVF maximum storage
limit for frozen ova, sperm and embryos to 55
years. The Health Secretary, Sajid Javid,
said the current limit of 10 years was ‘severely
restrictive’.
The current law allows ova, sperm or embryos
belonging to patients who are judged to be
'prematurely infertile', or likely to become so,
such as individuals and couples freezing ova or
sperm prior to chemotherapy for cancer treatment,
to be kept for up to 55 years. The proposed
legislation would revoke the distinction between
those who are, and those who are not, 'prematurely
infertile'. All patients would therefore be
treated equally.
Besides this equality aspect, the proposed changes
have been driven by the trend towards later
parenthood as well as advances in the
cryopreservation of gametes. Sperm has long
been successfully frozen. Now, modern
freezing techniques, known as vitrification, mean
that ova can be stored seemingly indefinitely and
without deterioration.
These proposals highlight yet other bioethical
problems with IVF. The procedure, with the
use of anonymous sperm donation, favours single
motherhood and regards it as just another
lifestyle choice rather than depriving the child
of a biological father. Moreover, permitting
the use of gametes of up to 55 years old will
burden a child with an unnaturally elderly
mother. Such IVF management has the
propensity to put adults at its centre rather than
the prospective children.
There will also need to be extra considerations
of, for example, the treatment of third party
sperm, ova and embryo donors in addition to the
issue of posthumous donations. The proposed
changes will require new legislation. This
will be dependent on the Parliamentary schedule
and, as yet, no date has been announced.
Surrogacy in the UK is
rising
Surrogacy – one of the seemingly least
objectionable and destructive of the assisted
reproductive techniques (ARTs), but one that is
overloaded with bioethical problems.
The number of men and women using it to raise and
nurture children is rising in England and
Wales. Recent research, co-led by Kirsty
Horsey of the University of Kent, has found that
nearly four times as many parents are using
surrogacy compared with ten years ago.
The research
obtained data from two sources, namely the
Ministry of Justice and Cafcass (Children and
Family Court Advisory and Support Service), a
non-departmental body that represents children's
best interests in family court cases in
England. The primary statistics were derived
from parental orders (POs). POs are court
orders which transfer legal parenthood to the
intended parents (IPs) who have commissioned a
surrogate to carry a child. This legal
transfer is necessary because under UK law the
person who gives birth, the surrogate, is deemed
to be the legal mother of the child.
Figures from the
Ministry of Justice showed that 117 POs were
granted in 2011. In 2019, this peaked at 444
with 413 awarded during 2020. Data obtained
from Cafcass focused on the number of same-sex
couples applying for POs. In 2014-15, there
were 69 such applications, rising to 139 in
2019-20 and 115 in 2020-21. In other words,
same-sex applicants now make up about a third of
all PO applications.
Laws governing surrogacy in the UK have remained
in place for almost four decades. Many
consider they are no longer fit for purpose.
The UK’s Law Commission is currently reviewing
them and is expected to publish its
recommendations in late 2022.
No baby, no fee
With one cycle of basic IVF costing around £5,000,
everyone knows that a course of IVF can be
expensive, crippling so in many cases.
Moreover, infertility is common, affecting 1 in 7
couples, and IVF availability on the NHS is
limited in extent and patchy in terms of location
– 80% of NHS groups fail to deliver the NICE
recommendation of three IVF cycles for women under
40. Hence, many couples go for private
treatment. Yet despite spending thousands of
pounds, racking up huge debts and even selling
their homes, many still have no baby. After
all, the overall success rate of IVF is a measly
24% or so.
Enter Care Fertility, one of the UK’s leading
private IVF providers, and their new arrangement
announced as a ‘no baby, no fee’ deal. It
means that certain women, who do not become
pregnant after three cycles of IVF, provided at a
discounted rate, would get a full refund on their
costs.
Care Fertility claims the package promises ‘peace
of mind’. Some fertility doctors, finance
brokers and former patients are concerned that the
funding is being brought in-house rather than by
traditional third-party financiers. They
maintain that, ‘We must keep financial and
clinical decisions separate.’ Otherwise they
fear that such agreements might lead to
overly-aggressive treatments. For example,
the excessive use of ovarian stimulation hormone,
a component of all IVF treatment cycles to
superovulate women, can cause dangerous
complications, such as ovarian hyperstimulation
syndrome (OHSS).
No doubt the battle among IVF clinics for
innovation, publicity and clients will
continue. The poor (emotionally and
financially) couples will remain as both patients
and customers. And somewhere there may even
be a child.
Euthanasia and Assisted Suicide
Assisted Dying Bill [HL]
Friday 22 October was another dreary, even dreadful,
day for the ‘morally sensitive’. It was the
day that Baroness (Molly) Meacher’s Assisted Dying
Bill received its Second Reading in the House of
Lords. The Bill would allow for someone, who
is terminally ill and expected to die within six
months, to request and be provided with a lethal
prescription of assisted suicide drugs, following
assessment by two doctors and approval from the High
Court. It read like a draft from the Dignity
in Dying organisation, formerly the Voluntary
Euthanasia Society – after all, the Baroness is its
current chairwoman.
The event started at 10.09 am and the House
adjourned at 5.56 pm, so it lasted almost 8
hours. It was not really a debate since no-one
was questioned. Instead it consisted of
roughly 3-minute speeches for and against the Bill’s
proposals. Listening was hard work – some
speeches were good, some bad, many
repetitious. On balance, they seemed to be
about 50 – 50 pro and con. Probably none of
them changed anyone’s mind.
There was far too much anecdotal stuff. Peer
after peer was eager to recount the frightful death
of a relative or constituent in pain and
misery. Where was the ethical approach to such
a great subject? Are we now to be governed by
feelings rather than principles? The one
welcome theme was praise for the wonders of
palliative care and the common call for its improved
funding, though this is often a ploy used by
pro-euthanasiasts to demonstrate their
broadmindedness and integrity.
There were two personal highlights. One came
from the astute Lord Carlile of Berriew. He
questioned why, on their fourth attempt, had the
Bill’s supporters not yet dealt with previous holes
in the safeguards. Furthermore, he pointed out
that ‘Clause 1 requires the consent of the Family
Division of the High Court before suicide can be
assisted.’ And, ‘Have the judges been
asked? There are but 20 Family Division
judges.’ He proposed a calculation. ‘Let
us suppose that 25% of those judges objected to the
jurisdiction on grounds of conscience … and that
there were 1,000 cases a year.’ And ’Each case
would be bound to take two or three days before the
court. In a sentence, the Family Division
would be swamped by those cases.’ ‘In my view,
parliamentary Bills founded on such fragile
safeguarding and analysis, especially after years of
trying to produce acceptable safeguards, should
really not be troubling your Lordships’
House.’ True, Baroness Meacher later replied
that, ‘The High Court has been consulted.’
However, Lord Carlile’s overload problem remains.
The second highlight came from the amiable Lord
Winston. Concerning misunderstandings about
the Bill, he said, ‘It raises the most important
moral question and needs clarity without
euphemism. “Assisted dying” could equally be
applied to palliative care, so the Bill’s title does
not represent what is really intended. The
word “euthanasia” – from the Greek “eu”, meaning
well or good, and “thanatos”, meaning death – is
what we are actually talking about.’ He wished
to amend the motion by adding, ‘but that this House
considers that the bill should refer to euthanasia
rather than assisted dying.’ He later withdrew
this on ‘the convention of the House … that we do
not move amendments at the end of a Second
Reading.’ Yet Lord Winston had made a serious
point. Many think that ‘assisted suicide’
would be a more precise title for the Bill rather
than ‘assisted dying’, which is a good description
of the work of palliative care.
In the end, there was no vote. This does not
indicate a victory for the Bill’s supporters, rather
it is a Second Reading procedural convention.
During the debate 66 peers spoke in favour of the
Bill, 62 in opposition and six, who could not
attend, were against the measure. Hansard
simply recorded, ‘Bill read a
second time and committed to a Committee of the
Whole House.’ There it will be
scrutinised line by line, with amendments discussed
and voted upon. When that will occur is
currently unknown. Because it is a Private
Member’s Bill, it would need government time to pass
to the House of Commons and through its various
Stages there. This currently seems
unlikely. It is understood that the Prime
Minister, Boris Johnson, would oppose any assisted
suicide legislation. Similarly, the Health
Secretary, Sajid Javid, is ‘understood to have made
clear to friends that he does not intend to vote to
relax the law.’
The history of assisted suicide legislation in the
UK has been one of chipping away. The 1961
Suicide Act stands as the robust statute,
decriminalising suicide and so protecting the
vulnerable, but punishing anyone who assists.
Since 2003, several attempts have been made with
increasingly revised bills to amend the Act – all
have failed. The last attempt in the House of
Commons was in 2015 by Rob Marris MP – it too failed
by 330 votes to 118.
This issue will not go away. We will again
have to rehearse that assisted suicide legislation
is unnecessary and dangerous. And again, we
will have to prepare those slippery slope
arguments. For instance, on the basis of the
outcomes in jurisdictions where it is lawful, the
stipulation of six months will soon be increased,
other safeguards will be breached, eligibility
criteria will be widened, patients with non-terminal
illnesses will qualify, the vulnerable will be
pursued, healthcare professions will be divided,
doctor-patient relationships will be riven,
substandard end-of-life care will be normalised, and
the entire medico-legal framework of UK society will
be changed for ever, for the worse.
The UK needs to legalise assisted suicide like the
proverbial hole in the head.
Assisted Dying for
Terminally Ill Adults (Scotland) Bill
Yet another Scottish assisted suicide proposal has
been lodged at the Scottish Parliament. The
proposer is Liam McArthur, MSP for the Orkney
Islands, and a member of the Scottish Liberal
Democrats.
The Bill, technically only a draft proposal, would
enable competent Scottish adults, who are terminally
ill, to be provided at their request with assistance
to end their life. Currently, a consultation
period is underway. This is due to end on 22
December 2021, then the responses will be analysed
and a final proposal presented to the Scottish
Parliament as a Member’s Bill. This may take
months, perhaps even two years.
All the usual failings of such legislation are
present in this proposal – patient vulnerability,
slippery slopes, lack of safeguards, and so
on. And there is a novel feature. It
suggests that patients who are unable to travel due
to terminal illness, or people living in small and
remote communities, might be excused personal
attendance with the required two independent doctors
and instead be assessed by remote consultations,
such as telemedicine, before being granted help to
commit suicide by lethal drugs sent in the
mail. It will be a sort of death via Zoom and
post.
Scotland’s First Minister, Nicola Sturgeon, has
spoken out against proposals to legalise assisted
suicide citing fears about safeguards.
Speaking before the previous Scottish debate on the
issue in 2015, she said, ‘I voted against it last
time and I haven't been convinced of assisted
suicide this time either. A major stumbling
block is the issue of sufficient safeguards. I
believe we should support people to live and I am
therefore in favour of good quality palliative
care.’
Since Scottish devolution in 1999, there have been
several failed attempts to bring the issue onto the
statute book. The most recent, in 2015, was
proposed Patrick Harvie, the Green MSP for
Glasgow. It fell by 82 votes to 36.
Euthanasia in the
Netherlands
An edition of Update on Life Issues
without another ghastly euthanasia
development from the Netherlands would be like a
year without Christmas. Once more, another
significant Dutch claim has been advanced.
First, a reminder from Germany. In February
2020, the Federal Constitutional Court declared that
suicide was a constitutional right. The Court
shockingly stated that, ‘The right to a
self-determined death is not limited to situations
defined by external causes like serious or incurable
illnesses, nor does it only apply in certain stages
of life or illness. Rather, this right is
guaranteed in all stages of a person’s
existence. It is thus not incumbent upon the
individual to further explain or justify their
decision; rather their decision must, in principle,
be respected by state and society as an act of
self-determination.’ This was, and still is,
bioethical dynamite. It rips up any inherent
value of human life. It dismantles all
safeguarding boundaries of a society. It is
human autonomy unfettered. It is death on
demand.
Now, this stance has apparently been picked up in
the Netherlands. It is spelled out in an
article entitled, ‘Intentionally ending one's own
life in the presence or absence of a medical
condition: A nationwide mortality follow-back
study’, by Martijn Hagens et
al., and published in SSM
– Population Health (September
2021).
The Dutch authors point out that, ‘Having a
classifiable medical condition is a prerequisite to
receive PAD (physician-assisted dying).’ They
explain, ‘This study estimates the frequency of
people who intentionally ended their own life’ that
is, without assistance from a physician. They
report that, ‘In 1.85% of all [Dutch] deaths in
2015, people intentionally ended their own life; of
which 0.50% by voluntarily stopping eating and
drinking, 0.20% by self-ingesting self-collected
medication, and 1.15% using other methods.’
Hagens and colleagues concluded that, ‘This raises
the question how to address the desire to die from
people whose wish to intentionally end their own
life is not rooted in a medical condition and
therefore fall outside this medical framework of
assistance in dying.’
In other words, how can the Dutch move way beyond,
indeed outside, the boundaries of their already
liberal euthanasia laws? This is a dangerous
attempt to remove the medical requirement for PAD in
the Netherlands. It is dangerous because it
potentially includes everyone. It is also
dangerous because it will prompt medical, legal and
political authorities to ponder it.
BMA goes neutral
The British Medical Association (BMA) is the trade
union and professional body for doctors and medical
students in the UK. For many years it has
maintained a policy of opposition to euthanasia and
assisted suicide, or, what it prefers to call PAD
(physician-assisted dying).
However, at its annual meeting on 14 September 2021,
its policy-making body (known as the representative
body) voted in favour of changing this official
stance of opposition to one of neutrality. The
vote was close, with 149 for, 145 against, and 8
abstentions. Put another way, it was 49% in
favour and 48% in opposition, with 3% abstaining.
This decision was informed by the results of a
survey of its members in February 2020. Of the
almost 30,000 doctors (19% of those invited) who
responded, 40% supported a change in the current
law, 33% favoured opposition, and 21% backed
neutrality. It is a confusing state of
affairs.
The BMA website explains, ‘This means we will
neither support nor oppose attempts to change the
law. We will not be silent on this issue,
however. We have a responsibility to represent
our members’ interests and concerns in any future
legislative proposals and will continue to engage
with our members to determine their views.’
A position of neutrality signals that British
doctors, as represented by the BMA, will not oppose
legislation, such as, for example, Baroness
Meacher’s Assisted Dying Bill. However, as one
doctor, Gillian Wright, said in the BMA debate,
’Neutrality means tacit approval and has enormous
political significance.’ Others say that
neutrality is the best policy for reflecting the
diverse views held by the BMA membership.
Others say neutrality can mask strong objections.
Whichever way the BMA’s change of policy is viewed,
neutrality is a middle of the road, a sitting on the
fence sort of stance. It is a standpoint with
no real conviction. If assisted suicide were
to be legalised, what would such doctors do?
Go with the flow?
Genetic
Technologies
CRISPR and sickle-cell and
β-thalassemia
Sickle-cell disease (SCD) and transfusion-dependent
β-thalassemia (TDT) are the most common single-gene
diseases in the world. Approximately 300,000
new cases of SCD and 60,000 of TDT are diagnosed
each year. They are particularly widespread
among people with an African or Caribbean family
background. Both diseases affect red blood
cells and are caused by mutations in the haemoglobin
β subunit gene (HBB).
SCD patients can suffer from vaso-occlusive crises,
or VOCs, which are responsible for blocking the
circulation system with sickled cells, and other
life-threatening events, such as stokes.
Patients with TDT invariably succumb to chronic
complications of iron overload, such as heart and
liver failure. Both diseases significantly
shorten long-term survival.
Although treatments are available, cures are what
are really needed. Currently, cures involve
rarely-matched donors and risky stem-cell or bone
marrow transplants.
Unveiled in 2012, CRISPR-Cas9 (Clustered Regularly
Interspaced Short Palindromic Repeats) is a powerful
technology that can be used to edit genes allowing
researchers to alter DNA sequences and modify gene
function. So, what can CRISPR do for SCD and
TDT? An insight is provided in a paper by
Haydar Frangoul et al.,
entitled ‘A CRISPR-Cas9 Gene Editing for Sickle Cell
Disease and β-Thalassemia’ that recently appeared in
the New England Journal of
Medicine (2021; 384:
252-260).
Two biotech companies, Vertex Pharmaceuticals and
CRISPR Therapeutics, have developed CTX001, a
proposed CRISPR-Cas9 gene-edited therapy for SCD and
TDT. It is known that patients with SCD or TDT
who co-inherit hereditary persistence of foetal
haemoglobin, in which foetal expression continues
into adulthood, exhibit little or no evidence of
either disease.
Two patients were enrolled in this preliminary
trial, one with SCD, the other with TDT. Both
were infused with CTX001 to reactivate the
production of foetal haemoglobin. BCL11A is a
transcription factor that represses foetal
haemoglobin synthesis. The research team used
CTX001 to reduce BCL11A expression and revive
production of foetal haemoglobin.
Approximately 80% of the targeted alleles were
modified, with no evidence of off-target
editing. So far, so good.
More than a year later, both female patients (19 and
33 years old) had continuing high levels of allelic
editing in bone marrow and blood, increases in
foetal haemoglobin that were distributed throughout
all cells, no need for blood transfusions, and (in
the patient with SCD) no vaso-occlusive
episodes. There were downsides – adverse
events included pneumonia, sepsis and abdominal
pain.
This was a ‘proof of principle’ trial. Initial
results were positive and the protocol warrants
further experimental testing of CRISPR-Cas9
gene-editing approaches to treat SCD, TDT and other
genetic diseases.
Brain organoids with eyes
Here comes another clash between scientific progress
and conservative, orthodox bioethics. The
culprit is a paper by Elke Gabriel et
al., entitled, ‘Human brain
organoids assemble functionally integrated bilateral
optic vesicles’ published in Cell
Stem Cell (2021, 28:
1740-1757).
This controversial work used 16 batches taken from
four donors of human induced pluripotent stem cells
(iPSCs) to create 314 brain organoids, 72% of which
formed a primitive eye structure called an optic
cup. The method is therefore considered to be
reproducible. These structures contained lens
and corneal tissue and they responded to light and
exhibited connections between the retina and regions
of the brain. It was around day 30 that these
brain organoids attempted to assemble optic
vesicles, which developed progressively as visible
structures within 60 days, similar to the rates
recorded in normal human embryo development.
According to the team leader, Jay Gopalakrishnan of
University Hospital Düsseldorf, ‘Our work
highlights the remarkable ability of brain organoids
to generate primitive sensory structures that are
light sensitive and harbour cell types similar to
those found in the body.’ And ‘These organoids
can help to study brain-eye interactions during
embryo development, model congenital retinal
disorders, and generate patient-specific retinal
cell types for personalized drug testing and
transplantation therapies.’ That is a concise,
Teutonic-like description of the work.
Many critics are less prosaic. They ask,
whether there should be limits on growing human
embryo-like structures which are becoming
increasingly complex. For example, Paul
Knoepfler of the University of California Davis
School of Medicine is mildly concerned. He has
written, ‘As to the human embryo models that are
starting to be so similar to actual human embryos, I
think limits make sense. For human brain
organoids not so much. These structures are
fairly far removed from actual human brains and
reports of neural activity in them don’t show
anything like coherent function on a consistent
basis.’
Here is a more bioethically-conservative
perspective. Of course, developments like
these can assist in the study of inherited eye
disorders, drug testing, transplant therapies, and
so on. But here is human brain tissue, albeit
primitive. Yet this is exactly how human
embryos develop, from undifferentiated stem cells to
differentiated tissues and organs. What
next? The Düsseldorf team already wants to
extend the viability of these organoids to allow the
development of more mature eye structures.
This and other examples of controversial human
research, such as three-parent embryos, human-animal
hybrids and embryonic stem-cell technologies, test
bioethical boundaries. The problem is that
such restrictions have a habit of being legally
extended or criminally breached. Consider the
current pressure to lengthen the 14-day rule for
human embryo experimentation, or the global
prohibition on human germline gene editing until the
2018 scandal of He Jiankui.
Experiments on non-embryos, such as brain organoids,
throw a spanner in the bioethical works. Of
course, such structures cannot become human beings,
yet they look like the products of human
development. At the least there is the yuck
factor. And again, how closely must such
embryo-like structures resemble natural embryos
before they too are considered human?
Be warned, slippery slopes exist. This year’s
brain organoid may become a little more brain-like
next year, and ad infinitum. There are some
areas of research that should be halted and remain
closed for ever. Is this one? Perhaps
not yet, but in the future, probably yes.
The WHO and gene editing
It was back in 2018 that He Jiankui announced to the
world that he had used CRISPR-Cas9 to create the
first gene-edited humans, the twins, Lulu and
Nana. The incident erupted into a vast volcano
of opposition – the aftershocks are still being
sharply felt. He got three years in prison, we
got an unprecedented bioethical controversy for
ever.
In 2019, the World Health Organization (WHO)
convened an Expert Advisory Committee on Developing
Global Standards for Governance and Oversight of
Human Genome Editing to investigate and report on
the affair. On 12 July 2021, the WHO actually
published not one, but three linked reports – a
position paper, a set of recommendations and a
framework for governance.
In essence, the Committee said it is too soon to
allow heritable germline gene-editing in
humans. Moreover, it recommended that the WHO,
and especially its Director General, take on the
role of global regulator in all things genomic
editing. To achieve this the Committee
proposed a threefold approach – the fostering of
international collaboration, the encouragement of
ethical reviews of human genome clinical trials, and
the promotion of equitable access to genomic
medicines resulting from this technology.
Although these recommendation have no legal power,
they will likely influence governmental
deliberations and funding authorities and so exert
an indirect worldwide impact. Already several
countries have gone beyond the WHO’s
proposals. Some have imposed moratoriums on
this sort of experimentation, and many have signed
up to a registry of relevant germline clinical
studies.
The WHO is not alone. In September 2020,
another committee consisting of members from the US
National Academy of Sciences and the UK Royal
Society, with representatives from ten countries,
came to a similar conclusion. That is, the
technology is not yet ready to use in human embryos
destined for reproductive procedures.
Not all is forbidden. Human non-reproductive,
somatic genome-editing trials are approved by the
WHO’s Committee. Indeed, such work is already
bearing fruit. For example, clinical trials
have shown promise in treating blood disorders
including sickle cell disease, some cancers and the
deadly, late-onset, genetic disease, transthyretin
amyloidosis.
At times, this subject seems like a counsel of
despair. We live in a mixed world with diverse
bioethical standards, how can anything significant
be proposed let alone agreed by all? Talk of
transparency, inclusiveness, social justice,
non-discrimination and respect for people sounds so
weedy. And how can wordy reports influence the
thinking and practices of governments and
scientists? And what about those rogue states
and anarchic scientific charlatans? But
something must be done, boundaries must be
constructed, laws must be enacted. To say and
do nothing is not only defeatist, it will encourage
the building of a dystopian world. Is that
what we want?
Stem-cell
Technologies
Ageing, bones
and stem cells
Your body is full of biological surprises.
For example, it started with just one cell, a
zygote. And as you age it still
fascinates. For example, think bones.
As you get older your bone mass becomes less and
your skeleton becomes more fragile. Such
changes are hugely complex and involve a myriad of
molecular and cellular processes. Besides
ageing, post-menopausal women experience an
additional route of bone loss associated with
their declining levels of oestrogen.
Bones, like all other body parts, are constantly
turning over. That is, their cells are
simultaneously dying and renewing so that new
material is replacing the old. In bones,
this dual process of accretion and resorption is
driven primarily by skeletal stem cells (SSCs)
affecting the opposing actions of osteoblasts
(accretion) and osteoclasts (resorption).
Ageing brings about changes in the function of
SSCs, which alters the balance of turnover of bone
and hence its mass.
Recent experiments with mice have clarified the
role of SSCs in the dynamics of this bone
turnover. Thomas Ambrosi and colleagues at
Stanford University School of Medicine, examined
the effects of intrinsic ageing-driven changes in
these SSCs as opposed to environmentally-driven
changes. They removed SSCs from the bones of
young (2-month-old) and aged (24-month-old)
mice. These SSCs were transplanted into
young recipient mice, in which the transplants
formed small masses of bone tissue.
Two key differences between young and aged SSCs
were reported. First, the bone mass produced
by aged SSCs was much smaller than that produced
by young SSCs. Second, aged SSCs exhibited
an increased ability to promote the formation of
osteoclasts, the blood-derived cell type
responsible for bone resorption. Ageing
therefore limits the ability of SSCs to maintain a
healthy flux between bone accretion and bone
resorption – so bone mass declines. Such
insights into the complexities of bone ageing may
suggest treatments for problems, such as loss of
skeletal integrity, fracture healing and
osteoporosis.
This work was reported as, ‘Aged skeletal stem
cells generate an inflammatory degenerative niche’
by Thomas Ambrosi et al., in Nature (2021, 597:
256-262).
Stem cells and baldness
A deficiency of stem cells in hair follicles
contributes to hair whitening and hair loss.
Understanding the mechanism may lead to treatments
to prevent baldness in humans.
Rui Yi and his colleagues at Northwestern
University, Illinois, found that in the hair of
ageing mice, stem cells change shape and escape
the structures they are housed in, subsequently
migrating away from the hair follicles.
Professor Li, the leader of the research,
commented, 'If I did not see it for myself I would
not have believed it.’ In addition, two
genes, Foxc1 and Nfatc1,
were identified as responsible for trapping the
stem cells in the hair follicle structure.
These genes are less active in older cells,
allowing the stem cells to escape. When mice
lacking these genes were bred, they showed
accelerated ageing, losing hair at four to five
months old, with only sparse, grey fur remaining
at 16 months. In other words, deletion of Foxc1 and Nfatc1 causes
hair loss.
Hair whitening and hair loss were previously
thought to be caused by stem cell death, a
function of ageing, but this work suggests a
different mechanism, known as stem cell
exhaustion. The discovery of the role of Foxc1 and Nfatc1 in
hair ageing could lead to potential hair loss
treatments in human patients, by preventing stem
cell escape from hair follicles.
This paper entitled, ‘Escape of hair follicle stem
cells causes stem cell exhaustion during aging’ by
Chi Zhang et al., was
published in Nature Ageing (2021, 1:
889-903).
The gift of stem cells
Beth Hill is a nurse from Sedgley in the West
Midlands. During the summer she entered a
competition and won two tickets for the UEFA Euro
2020 semi-final football match between England and
Denmark at Wembley on 7 July 2021.
Naturally she wanted to share the tickets with her
boyfriend, Sam Astley. Except that Sam had
to miss the match and watch it on TV from his
hospital bed because he had a prior appointment to
donate stem cells. He was about to undergo
the removal of bone marrow from his hip
bones. The prospect of watching England play
in a semi-final was exciting, but he quickly
realised that donating stem cells was ‘more
important than any football game’. He never
considered delaying the procedure.
Sam had made the appointment to donate bone marrow
after he had signed the Anthony Nolan Trust's
register at a football tournament organised by
Beth’s friend Simon Wilkes, who suffers from a
form of blood cancer himself.
In the event, Beth could not attend the match
either as a close colleague had tested positive
for Covid-19 at work and she had been required to
isolate. She said the anaesthetist had told
Sam that he had woken up after the stem-cell
procedure in hospital singing ‘It's Coming Home’.
Euro 2020 sponsor Vivo said it wanted to thank Mr
Astley for ‘his selfless lifesaving donation’ and
had arranged for him and his girlfriend to attend
the final match of England against Italy as its
guests. ‘We hope that both of them enjoy the
experience’, the Chinese smartphone manufacturer
added. Incidentally, after a penalty
shoot-out in extra time, Italy won the final 3 -
2. Stem-cell treatments also won.
Miscellaneous
Nuala Scarisbrick (1939 –
2021)
In 1970, Nuala and Jack Scarisbrick co-founded
LIFE - Save the Unborn Child. It was to
become the largest and most influential pro-life
charity in the UK. Informed by their Roman
Catholic faith and influenced by some of their
friends, they had come to realise that the 1967
Abortion Act was an iniquitous piece of
legislation and that they had to do something to
counter its adverse effects. They were
adamant that declaring to be against abortion was
not enough – positive, practical alternatives were
needed. There could be no circumstances that
justified aborting an unborn child.
Consequently Life took an absolutist stance.
Thousands and thousands of women and their
children are thankful that the Scarisbricks and
Life have supported and defended them through
difficult and unexpected pregnancies.
In the early days, Nuala and Jack were caring for
pregnant girls by taking them into their own
home. While Jack became the figurehead of
the new charity, it was Nuala who oversaw the
day-to-day running of Life. For 30 years,
she took on the full-time but unpaid position of
National Administrator. Jack described her
as Life’s ‘chief animator’. The
husband-and-wife team became the dynamic duo who
drove the charity until they stepped down from
their leadership roles in 2017. By then
Nuala had begun to experience the onset of
Alzheimer's.
And how thankful many of us are to have known
Nuala, for so many years, the châtelaine of Life
House, the matriarch of the Life family and the
doyenne of all things pro-life. To know her
was to admire her. Tireless defender of the
unborn, formidable organiser, generous hostess,
steadfast friend, gifted teacher, wellspring and
driver of ideas, fount of fun.
Nuala was a great encourager. In the early
1980s, many of us, educated by the Schaeffer and
Koop book and films, entitled Whatever
Happened to the Human Race? were
looking for an outlet to express our new-found
pro-life credentials. Nuala cheered us on to
form Evangelicals for Life, a specialist grouping
within the main organisation. It helped
broaden the UK’s pro-life constituency so that
being anti-abortion was no longer only a Roman
Catholic endeavour.
She was also a formidable realist – when we told
her we wanted to start the Aberystwyth Life Group,
her response was that nonchalant, ‘Oh, you want to
give it a go do you?’ but then reassuringly she
drove from Leamington Spa to Aberystwyth to spend
a weekend training us in Life education, caring
and political advocacy. She was almost
Wonder Woman!
Nuala Ann Scarisbrick (née Izod) was born in
January 1939 at St Thomas’s Hospital, London and
lived in Ewell, Surrey. She attended
Rosebery Grammar School for Girls in Epsom.
After university, she worked first for Unilever,
helping to launch the washing powder 'Daz', and
then briefly as an English literature teacher in
Reigate, Surrey. In 1965, she married the
distinguished Tudor expert, Professor John Joseph
‘Jack’ Scarisbrick. They first met when she
got into the same carriage of the Epsom/London
train one morning when Jack was on his way to
Queen Mary College, where he was teaching.
Nuala was going to University College, where she
was studying English literature. She had a
pile of books in her arms which she spilled across
the seat and floor when the train started.
Jack helped her recover them. They did not
exchange more than a few words –
Nuala had immediately plunged herself into one of
the retrieved books. They met ‘properly’ at
a smart cocktail party in Chelsea many months
later. Jack spotted her at the far corner of
a crowded room and managed to weave his way over
to her - to introduce himself. He had not
remembered that they had already ‘met’.
Her first words to him were ‘Have you got a clean
shirt on?’ He probably hadn’t! But as
Jack recalled, 'I fell for her totally. What
young(ish) man wouldn’t?' Three months later
we were married.
They made their home in Leamington Spa. They
have two daughters, eight grandchildren, and ten
great-grandchildren. How we loved her – how
we will now miss her. Our heartfelt
condolences go to Jack and the family – how
especially privileged they were to have known
Nuala for decades as wife, mother, grandmother and
great-grandmother. She died at home in
August 2021, surrounded by Jack and their
daughters.
Biological and
chronological clocks
How old are you? Some reply with a
chronological age. Some say they are only as
old as they feel. The better informed
declare they are as old as their arteries.
Welcome to the inflammatory ageing clock
(iAge). This is a new type of ‘clock’ that
can assess chronic inflammation to predict whether
someone is at risk of developing age-related
disorders, such as cardiovascular and
neurodegenerative diseases. The clock
measures a person’s ‘biological age’, which takes
health into consideration and can therefore be
higher or lower than a person’s chronological
age. Healthy people tend to have a
biological age lower than their chronological age.
It has been described in a paper entitled, ‘An
inflammatory aging clock (iAge) based on deep
learning tracks multimorbidity, immunosenescence,
frailty and cardiovascular aging’ by Nazish
Sayed et al., in Nature
Aging (2021, 1:
598-615).
The concept behind the iAge is based on the idea
that as a person ages, their body experiences
chronic, systemic inflammation – their cells
become damaged and emit inflammation-causing
molecules. This ultimately leads to wear and
tear on their tissues and organs. And
because people with a healthy immune system will
be more able to neutralise this inflammation, they
will age more slowly. In other words,
because inflammation is treatable, the iAge tool
could help doctors determine who would benefit
from medical intervention, such as
anti-inflammatory drugs, that should potentially
extend the number of years a person lives in good
health.
To develop iAge, the team at Stanford University
in California analysed blood samples from 1,001
people aged 8 to 96 years old. The
researchers used health information and a
machine-learning algorithm to identify protein
markers in blood that most clearly signalled
systemic inflammation. In particular, they
pinpointed the immune-signalling protein, or
cytokine, CXCL9. It is mainly produced by
the inner lining of blood vessels (including
arteries!) and has been associated with the
development of heart disease.
The researchers tested iAge on a cohort of
centenarians. The results showed the
volunteers had on average a biological age 40
years younger than their chronological age.
This further suggested that people with healthier
immune systems tend to live longer.
Measuring inflammation with the iAge clock could
prove to be a useful predictor of patient health
in a clinical setting.
Conscientious objection
reversed
Talk about abortion or euthanasia and the issue of
conscientious objection is never far away.
Not long ago, it was simple. For example,
Section 4 of the 1967 Abortion Act protected the
ethical stance of healthcare workers by stating
that individuals are under no obligation to
‘participate in any treatment authorised by [the
Act] to which [they have] a conscientious
objection.’ It has become a highly-contested
and poorly-resolved piece of legislation.
Nowadays, it is more commonly argued that doctors
have a duty of care to provide legal healthcare
services. Take, for example, an article by
Kyle Fritz, of the University of Mississippi, in The
American Journal of Bioethics (2021, 1:
46-59), entitled ‘Unjustified symmetry: Positive
Claims of Conscience and Heartbeat Bills.’
Interestingly, the legal code of Fritz’s home
state, Mississippi, declares, ‘A health-care
provider may decline to comply with an individual
instruction or health-care decision for reasons of
conscience.’ Fritz argues, quite
unconvincingly, that if some doctors are permitted
to withhold their
services on the grounds of conscientious
objection, why cannot other doctors provide their
services for the same reason? He calls the
current situation ethically ‘asymmetrical’.
Fritz writes, ‘… one’s integrity can be damaged
not only by performing an action contrary to one’s
conscience, but also by not performing an action
that one’s conscience requires. So, if we
should protect negative conscience clauses to
protect integrity, we should also protect positive
ones for the same reason.’
Fritz’s approval is long and complex. The
objection is more concise. If an act is
deemed legal, say abortion, then a negative
conscience clause is a performance of
charity. The act can be performed by
another. If an act is deemed illegal, say
euthanasia, then a positive conscience clause is a
performance of unlawfulness. And the law
should never encourage that which is illicit.
What would be the outcome of implementing Fritz’s
thesis? If both negative and positive
conscience clauses are allowed, then conscientious
objection becomes meaningless.
USA and Elsewhere
UPitt and foetal research
The University of Pittsburgh is in trouble. For
months it has been accused of operating a foetal research
programme with allegations that include the illegal
harvesting of kidneys from aborted babies while their
hearts were still beating. Moreover, this research
project at the University is also claimed to be unlawfully
supported by taxpayer’s money.
UPitt admits conducting ‘fetal tissue research’ ...
‘obtained from repositories called tissue banks’ and that
it ‘receives all fetal tissues from UPMC (University of
Pittsburgh Medical School) Magee-Womens Hospital.’
However, the University denies any illegal
activities. David Seldin, UPitt’s vice chancellor
for news has stated, ‘As we have repeatedly noted, the
University of Pittsburgh does not perform medical
procedures and is not part of the tissue collection
process. All of the University’s research is closely
supervised to ensure compliance with strict and rigorous
federal and state laws and regulations.’
Counter evidence has come from documents obtained from the
US Department of Health and Human Services through a
Freedom of Information Act request. The documents
are purported to show that the federal government gave the
University of Pittsburgh at least $2.7 million over the
last five years to become a ‘tissue hub’ for aborted baby
body parts for scientific research.
Such has been the media pressure that the University has
recently retained the Washington DC law firm of Hyman
Phelps & McNamara to prove its research is
legal. Moreover, state senators plan to introduce
legislation to instruct the Pennsylvania Auditor General,
Timothy DeFoor, and the Attorney General, Josh Shapiro, to
inspect the University. In the meantime, the
investigations, allegations and denials continue.
Francis Collins steps down
In early October, the 71-year-old Francis Collins
announced that he will step down as director of the US
National Institutes of Health (NIH) by the end of the
year. He said, ‘This is the right time, it’s the
right message, it’s the right decision.’ Collins has
led the US$41-billion biomedical agency through this
historic and deadly pandemic with courage and
aplomb. Appointed by then-president Barack Obama in
2009 and serving under three US presidents, Collins has
held the NIH role for longer than any other presidential
appointee.
Collins is renowned as a world-class geneticist.
Moreover, he has built a reputation as a savvy
spokesperson for scientific research, winning supporters
across party lines. Throughout the
politically-charged Covid-19 pandemic, he has been on the
frontlines urging Americans to wear face coverings and get
vaccinated.
He is sure his resignation decision is right. He has
been quoted as saying, ‘I’m not worried that if I walk
away by the end of the year, that will do any serious harm
to our contribution to fighting this pandemic.’ And
‘I am proud of all we’ve accomplished. I
fundamentally believe, however, that no single person
should serve in the position too long, and that it’s time
to bring in a new scientist to lead the NIH into the
future.’
Besides his scientific credentials, Collins has been known
as an outspoken conservative evangelical Christian.
He has spoken often and at length about his conversion
from atheism to Christianity. In 2006, he wrote a
book entitled, ‘The Language of God: A Scientist Presents
Evidence for Belief.’ The following year, he
founded, with his wife, Diane, The BioLogos Foundation, a
group that aims to reconcile religion and science and
argues that God created the world through evolution.
That ruffled many feathers among many evangelicals.
In addition, he has drawn the ire of pro-life groups
because of his support for using foetal tissue in medical
research.
Yet his robust Christian character and winsomeness are
undeniable. A typical example of his sweet bluntness
are seen in a recent statement in reference to the
Covid-19 vaccines. ‘For somebody who’s a believer,
this is what you could call an answer to prayer. If
we’ve all been praying to God to somehow deliver us from
this terrible pandemic, and what happens is these vaccines
get developed that are safe and effective, well, why
wouldn’t you want to say, “Thank you, God” and roll up
your sleeve?’ Last month, he admitted that he is ‘a
bit’ frustrated with fellow evangelicals who have
hesitated or refused to get vaccinated.
Happy, productive retirement, Francis.
Euthanasia in Australia
Talk about group membership, peer pressure or slippery
slopes reminds us that we are all influenced by those
around us, for good or ill. And it seems to be the
trend in euthanasia legalisation.
Take, for example, the Commonwealth of Australia. A
country of 26 million people spread out over six
states. By contrast, the United Kingdom is a country
of 60 million people spread out over four countries.
Yet we speak the same language, sort of.
But, as yet, we do not share the same bioethical values,
especially in terms of euthanasia and assisted
suicide. Both remain illegal in the UK. By
contrast, euthanasia legalisation has ripped through
Australia in less than five years. A convenient
starting point would be the 1997 Euthanasia Laws
Act. This removed the power of Parliament to
legalise euthanasia in the states. And so they fell,
not en masse, but one by one, and rapidly, just like a
clique of dominoes. First was Victoria in 2017
followed by Western Australia in 2019. The law in
these two states is now operational. Then, this
year, the bioethical momentum moved up a gear with
legalisation in Tasmania in March 2021, followed by South
Australia in June 2021 and Queensland in September
2021. The killing will start in these three states
within the next two years. So, now there is only one
Aussie outsider, New South Wales.
The legalisation of euthanasia is like a contagion – it
travels down that slippery slope, passing from neighbour
to neighbour. Who would bet against New South Wales
not joining the gang within the next two years?
Already in mid-October, Alex Greenwich, a New South Wales
independent MP, has tabled his Voluntary Assisted Dying
Bill 2021.
Extrapolate to the UK. So far, the four countries
have firmly resisted assisted suicide legislation.
But euthanasia bills are currently before the parliaments
at Westminster and Holyrood. What will stop
them? Who will stop them?
Abortion in Benin
Faced with a map of the world could you (honestly) put
your finger on Benin? That’s it, sandwiched between
Nigeria and Togo, the French-speaking land of 12 million
people. Well, if you can’t find it, abortion
certainly can.
In mid-October, after a heated debate, Benin’s parliament
voted to legalise abortion in most circumstances.
Benin therefore become one of only a handful of African
countries to do so, including Zambia, Cape Verde,
Mozambique, South Africa and Tunisia. By contrast,
several countries in Africa have total bans on abortion,
including Congo-Brazzaville, the Democratic Republic of
Congo, Djibouti, Egypt, Guinea-Bissau and Senegal.
Abortion in Benin was previously legal only in cases of
rape, or incest, or if the mother’s life was at risk, or
if the unborn child had a particularly serious medical
condition.
The new law says abortion may be permitted in the first 12
weeks of a pregnancy if the pregnancy is ‘likely to
aggravate or cause a situation of material, educational,
professional or moral distress incompatible with the
interests of the woman and/or the unborn child.’
However, the law still needs to be ratified by the
constitutional court before it can take effect.
According to Benin’s Health Minister, Benjamin Hounkpatin,
‘This measure is going to ease the pain of many women who,
faced with the distress of an unwanted pregnancy, find
themselves obliged to risk their lives by using unsafe
abortion methods.’ He estimated that unsafe
abortions are responsible for 20% of maternal deaths
across his country. However, the truth is that
abortion should never be regarded as healthcare.
Abortion in El Salvador
Keep that map of the world open. Now put your finger
on El Salvador. There it is, in South America,
bordered by Honduras and Guatemala, with a population of
6.5 million. See, this is not just an ‘Update on
Life Issues’!
The El Salvador constitution contains a right-to-life
article, passed in 1998. It recognises ‘as a human
person every human being from the moment of
conception.’ The country has one of the world’s
strictest laws on abortion. Elective abortion is
banned in all cases, including rape, incest and foetal
deformity. The penalty for mothers and for doctors
is between 2 and 8 years in prison. El Salvador is
under immense international pressure, from Western
governments, international groups and NGOs, to liberalise
its ban on abortion.
In mid-October, the Salvadorian Congress voted
overwhelmingly, 73 to 11, to maintain its current
law. The vote was in response to a petition brought
in September by women's rights groups, seeking exceptions
to the abortion ban.
After the vote, Rebeca Santos, congresswoman for the
ruling New Ideas Party, declared, ‘We have legislated in
favour of protecting life from its conception.’
Again, abortion should never be regarded as healthcare.